The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline
Shares of Bausch Health Companies Inc. (BHC) declined 6.3% after the company reported mixed results for the second quarter of 2025.Adjusted earnings per share of 90 cents missed the Zacks Consensus Estimate...
LAVAL, QC and CUPERTINO, Calif. , July 29, 2025 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), a global, diversified pharmaceutical company, and DURECT Corporation...
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:AlTi Global, Inc. ALTI is a financial company which provides merchant banking, corporate advisory, brokerage and placement agency...
Shares of Bausch Health Companies Inc. BHC declined 3.81% after the company reported lower-than-expected first-quarter 2025 results.Adjusted earnings per share of 59 cents missed the Zacks Consensus Estimate...
First Quarter Consolidated Revenues of $2.26 billion, up 5% on a Reported basis and 6% on an Organic (non-GAAP) 1 basis over the prior year period
A Long-Awaited Advancement in Non-Invasive Radiofrequency Skin Tightening Is Now Approved for the Canadian Market
The next generation of skin resurfacing technology will debut at the ASLMS 2025 Conference
Supplement In Response to Company Learning that Carl Icahn and Affiliates Have Cash-Settled Equity Swaps for Approximately 90 Million of Its Common Shares
LAVAL, QC / ACCESS Newswire / April 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), and its gastroenterology business Salix Pharmaceuticals, Inc., today...